UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
UvA-DARE (Digital Academic Repository)
B cells and B cell directed therapies in rheumatoid arthritis: towards
personalized medicine
Thurlings, R.M.
Publication date
2011
Link to publication
Citation for published version (APA):
Thurlings, R. M. (2011). B cells and B cell directed therapies in rheumatoid arthritis: towards
personalized medicine.
General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s)
and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open
content license (like Creative Commons).
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please
let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material
inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter
to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You
will be contacted as soon as possible.
PAGE.
–
PAGE.
7
–
CHAPTER (p11/21) General introduction
CHAPTER (p23/37) Lymphoid neogenesis does not define a specific clinical rheumatoid
arthritis phenotype ARTHRITIS RHEUM. 008;58:58-9
CHAPTER (p39/55) The relationship between synovial lymphocyte aggregates and the clinical
response to infliximab in rheumatoid arthritis: A prospective study ARTHRITIS RHEUM. 009;0:7-4
CHAPTER 4 (p57/71) Early effects of rituximab on the synovial cell infiltrate in patients with
rheumatoid arthritis ARTHRITIS RHEUM. 007;5:77-8
CHAPTER 5 (p73/79) CD22 is not expressed merely on B cells: comment on the article by
Vos et al; Author reply ARTHRITIS RHEUM. 008;58: 9-
CHAPTER (p81/101) Synovial tissue response to rituximab: mechanism of action and identifica
tion of biomarkers of response ANN RHEUM DIS. 008;7:97-5
CHAPTER 7 (p103/119) The relationship between the type I interferon signature and the response
to rituximab in rheumatoid arthritis ARTHRITIS RHEUM. 00 AUG 8. [EPUB AHEAD OF PRINT]
CHAPTER 8 (p121/131) Clinical response, pharmacokinetics, development of human antichimeric
antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis
ANN RHEUM DIS. 009;9:409-
TABLE OF CONTENTS
Table of contents
PAGE. 8 – PAGE. 9 –
CHAPTER 9 (p133/147) Disease activity-guided rituximab therapy in rheumatoid arthritis: the
effects of re-treatment in initial non-responders versus initial responders ARTHRITIS RHEUM. 008;58:57-4
CHAPTER 0 (p149/153) Re-treatment of rheumatoid arthritis patients who were initial
nonresponders to rituximab: comment on the article by Thurlings et al; author reply
ARTHRITIS RHEUM. 009;0:87-8
CHAPTER (p155/177) Atacicept in patients with rheumatoid arthritis: results of a multicenter,
phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study
ARTHRITIS RHEUM. 008;58:-7
CHAPTER (p179/189) General discussion
(p190/192) English summary
(p194/196) Nederlandse samenvatting
(p198/200) Dankwoord
(p201) Curriculum vitae
(p202/203) Publication list
(p205/210) Color print section
